SRI-22818 is a NF-κB activator with an EC 50 of 0.5 μM. SRI-22818 upregulates the expression of NF-κB and promotes its activation. SRI-22818 increases the level of SOD2 . SRI-22818 exhibits activity in the SOD1 G93A model of amyotrophic lateral sclerosis (ALS). SRI-22818 can be used for research related to amyotrophic lateral sclerosis.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Amyotrophic Lateral Sclerosis | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > SOD
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.